Phrontline Biopharma has closed a $60 million Pre-A+ financing round that will significantly expand the company’s global development of bispecific and dual-payload antibody drug conjugates. Lapam Investment led the round with participation from Samsung Venture Investment Corporation, Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing investors Decheng Capital, Medfine Health Fund, and C&D Emerging Investment also increased their commitments.
The funding will support advancing the company’s clinical and preclinical ADC pipeline, expanding international clinical operations, and strengthening strategic global partnerships.
Founded in 2022, Phrontline has become an early mover in bispecific antibody ADCs and dual-payload ADCs. The company has built an end-to-end ADC technology platform that supports antibody discovery, linker payload engineering, site-specific conjugation, and detailed functional characterization. This platform has enabled the design of several dual-target combinations and complementary payload strategies tailored to specific tumor indications. Nearly ten ADC candidates have emerged from this effort, including TJ101, a bispecific ADC targeting EGFR and B7 H3. TJ101 is currently enrolling patients in first-in-human trials being conducted in both China and the United States. Preclinical research shows strong efficacy and safety relative to peer programs.
Recent partnerships are reinforcing the company’s global strategy. On October 20, 2025, Phrontline announced a collaboration with Samsung Bioepis to develop two next-generation bispecific and dual-payload ADC candidates jointly. On October 31, 2025, the company entered an exclusive license agreement with Sino Biopharmaceutical for the development and commercialization of TJ101 in Mainland China and the Hong Kong SAR. The deal includes an upfront payment along with future milestones and royalty opportunities.
Phrontline’s leadership and investors emphasized that the latest financing will accelerate the advancement of its next-generation ADC technologies while enabling broader global reach. The company plans to use the newly raised capital to advance its clinical programs, build its development capabilities, and deepen its partnerships in major markets.
KEY QUOTES:
“From the beginning, our strategy has been guided by biology and translational science. We believe that dual-target synergy and complementary payload mechanisms can unlock new therapeutic options for patients whose tumors are resistant to current therapies. Our preclinical and emerging clinical data are beginning to validate this vision.”
Tony Chen, Ph.D., Founder and Chief Executive Officer of Phrontline Biopharma
“We are deeply grateful to both our new and existing investors for their continued confidence in Phrontline. This financing marks an important milestone for the company and will allow us to accelerate our clinical programs and global expansion as we work to deliver truly innovative ADC medicines to patients around the world.”
Tony Chen, Ph.D., Founder and Chief Executive Officer of Phrontline Biopharma
“Phrontline is a highly execution-focused and resilient team. By leveraging its proprietary bispecific antibody and dual-payload ADC platforms, the company has built a differentiated pipeline aimed at major unmet medical needs. Its preclinical data show compelling efficacy and safety and demonstrate the strong scalability of its platform. We look forward to supporting Phrontline as its programs advance through clinical development and as the company continues to drive innovation in next-generation ADC therapeutics.”
Ji Wang, Investment Lead at Lapam Investment
